Valganciclovir
- Generic Name
- Valganciclovir
- Brand Names
- Valcyte
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N6O5
- CAS Number
- 175865-60-8
- Unique Ingredient Identifier
- GCU97FKN3R
- Background
Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
- Indication
Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
- Associated Conditions
- Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis
- Associated Therapies
- -
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Conditions
- Interventions
- Drug: Tranexamic acid (TXA)Drug: HydrocodoneDrug: labetalolDrug: metforminDrug: nifedipineDrug: oxycodoneDrug: clindamycinDrug: azithromycinDrug: escitalopramDrug: sertralineDrug: CiprofloxacinDrug: ondansetronDrug: DoxycyclineDrug: LevofloxacinDrug: MethylphenidateDrug: CitalopramDrug: SumatriptanDrug: CyclobenzaprineDrug: FurosemideDrug: RosuvastatinDrug: GabapentinDrug: HydrochlorothiazideDrug: HydroxyureaDrug: TrazodoneDrug: TopiramateDrug: ValganciclovirDrug: RemdesivirDrug: VenlafaxineDrug: VerapamilDrug: FluvoxamineDrug: AnakinraDrug: TocilizumabDrug: AmoxicillinDrug: BupropionDrug: BuprenorphineDrug: LevetiracetamDrug: ParoxetineDrug: Duloxetine
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Duke University
- Target Recruit Count
- 1600
- Registration Number
- NCT03511118
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Loma Linda University Health, Loma Linda, California, United States
Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)
- Conditions
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 601
- Registration Number
- NCT03443869
- Locations
- 🇺🇸
University of Chicago ( Site 0251), Chicago, Illinois, United States
🇺🇸Brigham & Women's Hospital ( Site 0244), Boston, Massachusetts, United States
🇺🇸The Ohio State University Wexner Medical Center ( Site 0264), Columbus, Ohio, United States
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Viracta Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03397706
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
Asymptomatic Congenital CMV Treatment
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2023-01-26
- Target Recruit Count
- 7
- Registration Number
- NCT03301415
- Locations
- 🇺🇸
University of Alabama - Children's of Alabama - Clinical Virology, Birmingham, Alabama, United States
🇺🇸Arkansas Children's Hospital - Infectious Diseases, Little Rock, Arkansas, United States
🇺🇸University of Louisville School of Medicine - Norton Children's Hospital - Infectious Diseases, Louisville, Kentucky, United States
Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- National Institute of Cancerología
- Target Recruit Count
- 40
- Registration Number
- NCT03296553
- Locations
- 🇲🇽
Instituto Nacional de Cancerologia, Mexico city, Mexico
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Albert Park
- Target Recruit Count
- 52
- Registration Number
- NCT03107871
- Locations
- 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸Saint Louis Universtiy, Saint Louis, Missouri, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2016-12-02
- Target Recruit Count
- 450
- Registration Number
- NCT02973464
- Locations
- 🇨🇳
the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
- Conditions
- Interventions
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 352
- Registration Number
- NCT02931539
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 553
- Registration Number
- NCT02927067
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT02871401
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.